---
title: "Amgen hits record high as Tezspire phase 3 trial succeeds"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302733313.md"
description: "Amgen rose 2% to $447.09 after Tezspire showed significant remission in Phase 3 eosinophilic esophagitis trial."
datetime: "2026-10-22T14:06:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302733313.md)
  - [en](https://longbridge.com/en/news/302733313.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302733313.md)
generator: "portal-rs"
---

# Amgen hits record high as Tezspire phase 3 trial succeeds

Amgen (AMGN.US) climbed more than **2%** during regular trading to **$447.09**, hitting an intraday record high.

The company and AstraZeneca announced positive results from the Phase 3 CROSSING trial of Tezspire for eosinophilic esophagitis. The drug achieved significant histologic remission and sustained symptom reduction over 52 weeks compared with placebo, with a consistent safety profile.

Separately, RBC Capital Markets raised its price target on Amgen to **$430** from **$400**, maintaining an Outperform rating.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)

## Related News & Research

- [FDA warns Amgen over cancer drug promotional video](https://longbridge.com/en/news/303273297.md)
- [Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer](https://longbridge.com/en/news/302966836.md)
- [AMGN: DeLLphi-305 showed a significant survival benefit for first-line maintenance IMDELLTRA plus IMFINZI](https://longbridge.com/en/news/302970188.md)
- [AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026 | AMGN Stock News](https://longbridge.com/en/news/303279661.md)
- [Amgen, AstraZeneca Drug Combo Shows Promising Survival Results in Tough-To-Treat Lung Cancer](https://longbridge.com/en/news/303091953.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**